Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALBIREO PHARMA, INC.ALBO · Entity 116015 | Chief Medical Officer | October 22, 2021 | October 25, 2021 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Medical Officer | March 18, 2024 | March 20, 2024 |
| TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285 | Chief Medical Officer | June 13, 2017 | June 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALBIREO PHARMA, INC.
Report date October 22, 2021 · Filed October 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,355 |
Reported balance
After 2021-10-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-10-22 · Sale · Disposed 95 · Balance 12,355 F1: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $28.9187, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3: Represents 5,292 shares of common stock and 7,063 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $28.9187, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3: Represents 5,292 shares of common stock and 7,063 restricted stock units.
Fulcrum Therapeutics, Inc.
Report date March 18, 2024 · Filed March 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.12 · Expires 2034-03-17 | Direct | 400,000 |
Reported balance
After 2024-03-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-18 · Grant · Acquired 400,000 · Balance 400,000 F1: This option was granted on March 18, 2024 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of March 18, 2024. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on March 18, 2024 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of March 18, 2024. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.
TETRAPHASE PHARMACEUTICALS INC
Report date June 13, 2017 · Filed June 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2017-06-13 transaction · row 1
1 source rowRow 1 · 2017-06-13 · Exercise / conversion · Acquired 10,000 · Balance 10,000 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2021-01-02 | Direct | 47,689 |
Reported balance
After 2017-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-13 · Exercise / conversion · Disposed 10,000 · Balance 47,689 F1: This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2024 Filed Mar 20, 2024 16:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000950170-24-034177 · ownership.xml · derivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-03-17 F1 · derivative.exercise_date: This option was granted on March 18, 2024 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of March 18, 2024. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 18:41 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 95 | $28.83 | $2,738.85 |
DisclosureSEC source: 0001209191-21-061561 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,355 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $28.9187, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 5,292 shares of common stock and 7,063 restricted stock units. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 16:06 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 90 | $34.13 | $3,071.70 |
DisclosureSEC source: 0001209191-21-048161 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 5,075 shares of common stock and 7,375 restricted stock units. Includes 647 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2021. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 18:10 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 90 | $31.75 | $2,857.50 |
DisclosureSEC source: 0001209191-21-028377 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,893 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 4,205 shares of common stock and 7,688 restricted stock units. Includes 940 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019, 13 shares of common stock acquired under the ESPP on November 30, 2019, and 1,205 shares of common stock acquired under the ESPP on May 31, 2020. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 17:37 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 110 | $34.62 | $3,808.20 |
DisclosureSEC source: 0001209191-21-005154 · doc4.xml · nonDerivative · entry 2 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,825 F3 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F4 · balance_after: Represents 1,825 shares of common stock and 8,000 restricted stock units. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 17:37 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 23,700 | $0.00 Strike: $34.88 | $0.00 |
DisclosureSEC source: 0001209191-21-005154 · doc4.xml · derivative · entry 3 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 Underlying: Common Stock · 23,700 shares Expires 2031-01-20 F5 · derivative.exercise_date: This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 17:37 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005154 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,935 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025. F2 · balance_after: Represents 1,622 shares of common stock and 8,313 restricted stock units. Includes 150 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 16:21 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 89 | $34.55 | $3,074.95 |
DisclosureSEC source: 0001209191-20-055676 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,285 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 1,472 shares of common stock and 2,813 restricted stock units. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 16:15 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 91 | $25.80 | $2,347.80 |
DisclosureSEC source: 0001209191-20-043473 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,374 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 1,249 shares of common stock and 3,125 restricted stock units. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:22 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 92 | $17.64 | $1,622.88 |
DisclosureSEC source: 0001209191-20-025646 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,465 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 1,027 shares of common stock and 3,438 restricted stock units. Read SEC document |
| January 22, 2020 Filed Jan 23, 2020 19:28 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 443 | $24.29 | $10,760.47 |
DisclosureSEC source: 0001209191-20-004742 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,557 F1 · kind: Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 807 shares of common stock and 3,750 restricted stock units. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 19:28 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $24.67 | $0.00 |
DisclosureSEC source: 0001209191-20-004742 · doc4.xml · derivative · entry 2 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2030-01-20 F3 · derivative.exercise_date: This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:48 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $24.04 | $0.00 |
DisclosureSEC source: 0001209191-19-005241 · doc4.xml · derivative · entry 2 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2029-01-21 F2 · derivative.exercise_date: This option vests as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:48 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005241 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. F1 · balance_after: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 16:14 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $31.54 | $0.00 |
DisclosureSEC source: 0001209191-18-045819 · doc4.xml · derivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2028-08-05 F1 · derivative.exercise_date: This option vests and becomes exercisable as to 25% of the underlying shares on August 6, 2019 and the remainder in equal quarterly installments through the fourth anniversary of the date of grant. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 16:07 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-17-039812 · doc4.xml · derivative · entry 2 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,689 Underlying: Common Stock · 10,000 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 16:07 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | Exercise / conversionCommon Stock | 10,000 | $2.03 | $20,300.00 |
DisclosureSEC source: 0001209191-17-039812 · doc4.xml · nonDerivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 18:13 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006849 · doc4.xml · derivative · entry 1 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration. F2 · derivative.exercise_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2020. F2 · derivative.expiration_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2020. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 18:13 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantEmployee Stock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001209191-17-006849 · doc4.xml · derivative · entry 2 Horn Patrick Taylor · CIK 0001572002 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2027-01-29 F3 · derivative.exercise_date: Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/30/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.